Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;96(6):E210-E214.
doi: 10.1002/ajh.26167. Epub 2021 Apr 9.

Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders

Irene Defrancesco  1   2 , Marcella Visentini  3   4 , Silvia Zibellini  2 , Ylenia Aura Minafò  3   5   6 , Sara Rattotti  2 , Virginia Valeria Ferretti  7 , Ettore Rizzo  8 , Marzia Varettoni  2 , Marco Frigeni  2   9 , Alessandro Pulsoni  3 , Milvia Casato  3 , Stefania Colantuono  3 , Marianna Rossi  2 , Chiara Candido  2 , Caterina Zerbi  10 , Fabio Bergamini  10 , Caterina Cristinelli  10 , Nicole Fabbri  10 , Michele Merli  11 , Valentina Zuccaro  12 , Raffaele Bruno  1   12 , Marco Paulli  10   13 , Luca Arcaini  2   10
Affiliations

Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders

Irene Defrancesco et al. Am J Hematol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

None of the authors has relevant conflicts of interest related to the content of this work.

L.A. received advisory honoraria from Roche, Celgene, Janssen‐Cilag, Verastem, Eusa Pharma, and Incyte, research support from Gilead, and travel expenses from Roche, Celgene, Janssen‐Cilag, and Eusa Pharma. E.R. has shares of enGenome srl, an Italian bioinformatics company. A.P. was an advisory board member for Roche, Merk, Pfizer, Sandoz, and Takeda and a speaker for Roche, Gilead, and Bristol Myers Squibb. M.V. received advisory honoraria from Janssen, Roche, Astra Zeneca and travel expenses from AbbVie. R.B. was an advisory board member and a speaker for AbbVie, Gilead Sciences and Merck Sharp & Dohme.

Figures

FIGURE 1
FIGURE 1
Pattern of somatic mutations in 27 patients with B cell lymphoproliferative disorders associated to hepatitis C virus. (A), Prevalence of driver genetic lesions according to the involved pathway; (B), Circos plots representing the relative frequencies and pairwise co‐occurrence of the involved pathways according to IGHV usage; (C), Circos plots representing the relative frequencies and pairwise co‐occurrence of the involved pathways and IGLV rearrangements according to light chains CDR3 sequences
See this image and copyright information in PMC

References

    1. Arcaini L, Besson C, Frigeni M, et al. Interferon‐free antiviral treatment in B‐cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527‐2532. - PubMed
    1. Frigeni M, Besson C, Visco C, et al. Interferon‐free compared to interferon‐based antiviral regimens as first‐line therapy for B‐cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34(5):1462‐1466. - PubMed
    1. Minafò YA, Del Padre M, Cristofoletti C, et al. A stereotyped light chain may shape virus‐specific B‐cell receptors in HCV‐dependent lymphoproliferative disorders. Genes Immun. 2020;21(2):131‐135. - PubMed
    1. Defrancesco I, Zibellini S, Boveri E, et al. Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis. Hematol Oncol. 2020;38:689‐697. - PubMed
    1. Varettoni M, Zibellini S, Defrancesco I, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102(12):2077‐2085. - PMC - PubMed

Publication types

MeSH terms

Substances